Views & Analysis In the healthcare and life sciences jungle – industry must a... As the digital revolution takes hold, life sciences companies must evolve or face the consequences.
Views & Analysis The convergence of healthcare: when digital and medical coll... How traditional and digital approaches are being brought ever closer together in healthcare.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.